Periostin/OSF-2 Antibody (613643R) [Unconjugated]

Recombinant Human Periostin/OSF‑2 protein was serially diluted 2-fold and captured by Mouse Anti-Human Periostin/OSF‑2 Monoclonal Antibody (Catalog # MAB35483) coated on a Clear Polystyrene Microplate (Catalog # DY990). Mouse Anti-Human Periostin/OSF‑2 Monoclonal Antibody (Catalog # MAB35484) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).

• Reactivity: Hu
• Applications: ELISA
• Clone: 613643R
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Periostin/OSF-2 Antibody (613643R) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Periostin/OSF-2
  Met1-Gln836
  Accession # Q15063
• Specificity: Detects human Periostin/OSF-2 in direct ELISAs.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Periostin/OSF-2 Antibody (613643R) [Unconjugated]

• Fasciclin I-like
• MGC119510
• MGC119511
• OSF2
• OSF-2
• OSF-2osteoblast specific factor 2 (fasciclin I-like)
• OSF2periodontal ligament-specific periostin
• Osteoblast-specific factor 2
• PDLPOSTN
• periostin isoform thy2
• periostin isoform thy4
• periostin isoform thy6
• periostin isoform thy8
• Periostin
• periostin, osteoblast specific factor
• PNRP11-412K4.1
• POSTN
• TRIF52

Background

Periostin, also known as OSF-2, is a secreted matricellular protein with functions in extracellular matrix formation, cell migration, and inflammation (1). It is secreted as a 90 kDa monomer that can aggregate into >170 kDa higher-order multimers (2). Periostin contains an N-terminal EMI domain followed by four tandem FAS1 domains [takeshita]. Mature human Periostin shares 91% aa sequence identity with mouse and rat Periostin. Alternative splicing generates additional isoforms with various deletions in the C-terminal region following the FAS domains. Periostin is expressed by mesenchymal cells such as vascular smooth muscle cells, fibroblasts, osteoblasts, and odontoblasts in developing teeth (4-7). It is up-regulated in many carcinomas (2, 8). Periostin binds to Integrins alpha _v beta ₃ and alpha _v beta ₅ (2, 9), leading to enhanced cell adhesion and cell migration (2, 5, 6). It enhances Fibronectin and Collagen I production and promotes collagen fibrillogenesis (10, 11). It also induces epithelial-mesenchymal transition, tumor growth, invasion, and metastasis (9). Periostin induces the expression of VEGF R2 on endothelial cells and VEGF-C in tumor cells, and it can induce tumor lymphangiogenesis (8, 12). Periostin plays an important role in heart valve development and tissue healing after myocardial infarction (5, 13, 14). In asthma, it is up-regulated in bronchial epithelium and plays both destructive and protective roles by inducing eosinophil infiltration and inhibiting goblet cell metaplasia and mucus production, respectively (15, 16).

1. Liu, A.Y. et al. (2014) Matrix Biol. 37:150.
2. Gillan, L. et al. (2002) Cancer Res. 62:5358.
3. Takeshita, S. et al. (1993) Biochem. J. 294:271.
4. Kruzynska-Frejtag, A. et al. (2004) Dev. Dyn. 229:857.
5. Lindner, V. et al. (2005) Arterioscler. Thromb. Vasc. Biol. 25:77.
6. Horiuchi, K. et al. (1999) J. Bone Miner. Res. 14:1239.
7. Li, G. et al. (2006) Atherosclerosis 188:292.
8. Shao, R. et al. (2004) Mol. Cell. Biol. 24:3992.
9. Yan, W. and R. Shao (2006) J. Biol. Chem. 281:19700.
10. Erkan, M. et al. (2007) Gastroenterology 132:1447.
11. Norris, R.A. et al. (2007) J. Cell. Biochem. 101:695.
12. Kudo, Y. et al. (2012) PLoS One 7:e44488.
13. Snider, P. et al. (2008) Circ. Res. 102:752.
14. Kuhn, B. et al. (2007) Nat. Med. 13:962.
15. Blanchard, C. et al. (2008) Mucosal Immunol. 1:289.
16. Sehra, S. et al. (2011) J. Immunol. 186:4959.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q15063()